Professor of Medicine
Oncology
Dr. Muzaffar H. Qazilbash, MD
|
|
Give Review
Muzaffar Qazilbash works in the field of Oncology. He graduated from Dow Medical College. Dr. Muzaffar H. Qazilbash is a published doctor. He has 100 papers published. The most current publication "Transfection of interleukin-12 cDNAs into tumor cells induces cytotoxic immune responses against native tumor: implications for tumor vaccination." Muzaffar H. Qazilbash, MD accepts Medicare payments and is registered with Medicare.gov.
Publications
- Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review.
- Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.
- Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis.
- Autologous hematopoietic stem Cell transplantation in light chain amyloidosis (AL) with renal involvement.
- Pure Red Cell Aplasia in Major ABO Mismatched Allogeneic Hematopoietic Stem Cell Transplantation is Associated with Severe Pancytopenia.
- Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
- Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
- Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk Myeloma.
- High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis.
- Enforced fucosylation of cord blood hematopoietic Cells accelerates neutrophil and platelet engraftment after transplantation.
- Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hemato...
- Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem Cell transplantation for relapsed myeloma.
- Clinical Significance of Acquired Cytogenetic Clones in Patients With Treated Follicular Lymphoma.
- Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen-Matched Unre...
- Short-term cardiac toxicity of autologous hematopoietic stem Cell transplant for multiple myeloma.
- Donor Cell-Derived Myelodysplastic Syndrome With Ring Chromosome 7 After Allogeneic Hematopoietic Stem Cell Transplant in 2 Patients With Lymphomas as Primary Disease.
- Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective Analysis with 14-year follow-up.
- The association of diabetes and anti-diabetic medications with clinical outcomes in multiple Myeloma.
- Clinically silent clonal cytogenetic abnormalities arising in patients treated for lymphoid neoplasms.
- Lenalidomide Maintenance for High-Risk Multiple Myeloma after Allogeneic Hematopoietic Cell Transplantation.
- Value of novel agents and intensive therapy for patients with multiple Myeloma.
- Inflammatory Markers and Development of Symptom Burden in Patients with Multiple Myeloma during Autologous Stem Cell Transplantation.
- The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation.
- Durable responses with autologous hematopoietic SCT in patients with POEMS Syndrome.
- The Effect of Peritransplant Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
- Peripheral blood stem Cell yield calculated using preapheresis absolute CD34+ Cell count, peripheral blood volume processed, and donor body weight accurately predicts ...
- Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor Cell mobilization.
- Impact of t(11;14)(q13;q32) on the Outcome of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.
- Outcomes in patients with relapsed or refractory Acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation.
- Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes.
- A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients w...
- Plasma Cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients wit...
- Mechanistic studies on the synergistic cytotoxicity of the nucleoside Analogs gemcitabine and clofarabine in multiple myeloma: Relevance of p53 and its clinical implic...
- Outcomes of adults with Acute lymphoblastic leukemia (ALL) following relapse post allogeneic hematopoietic stem cell transplantation (HSCT).
- High-dose chemotherapy and Autologous Stem Cell Transplantation For Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL).
- Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience.
- Incidence and natural history of pure red Cell aplasia in major ABO-mismatched haematopoietic Cell transplantation.
- Cord-blood engraftment with ex vivo mesenchymal-Cell coculture.
- Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome.
- High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-Cell transplantation in patients with refractory lymphoid malignancies.
- Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with Acute lymphoblastic leukemia.
- Significance of Persistent Cytogenetic Abnormalities at Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission.
- Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation.
- Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplant.
- Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in Myeloma patients.
- Clofarabine Combined with Busulfan Provides Excellent Disease Control in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell...
- Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL.
- Durable Responses after Donor Lymphocyte Infusion for Patients with Residual Multiple Myeloma following Non-myeloablative Allogeneic Stem Cell Transplantation.
- Predictors of prolonged survival after allogeneic hematopoietic stem Cell transplantation for multiple myeloma.
- Donor leukocyte infusions (DLIs) in recurrent hodgkin lymphoma (HL) following allogeneic stem cell transplantation: ten-year experience at the M.D. anderson Cancer cen...
- Durable remission with salvage second autotransplants in patients with multiple Myeloma.
- Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic Cell transplantation.
- Retrospective Analysis of weekly intravenous immunoglobulin prophylaxis versus intravenous immunoglobulin by IgG level monitoring in hematopoietic stem cell transplant...
- A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.
- Feasibility of autologous hematopoietic stem Cell transplant in patients aged â¥70 years with multiple myeloma.
- Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with Acute myeloid leukemia or myelodysplastic ...
- Primary systemic amyloid light chain amyloidosis decompensating after filgrastim-induced mobilization and stem-Cell collection.
- Steroid-Refractory Acute GVHD: Predictors and Outcomes.
- Reduced-intensity allogeneic hematopoietic stem Cell transplantation for relapsed multiple myeloma.
- The outcome of IgD myeloma after autologous hematopoietic stem Cell transplantation is similar to other Ig subtypes.
- Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of Acute graft-versus-host disease.
- Outcome of allogeneic hematopoietic stem Cell transplantation in patients with low left ventricular ejection fraction.
- Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem Cell tra...
- Autologous hematopoietic stem Cell transplantation may reverse renal failure in patients with multiple myeloma.
- Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial.
- In-hospital complications of autologous hematopoietic stem Cell transplantation for lymphoid malignancies: clinical and economic outcomes from the Nationwide Inpatient...
- Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in Myeloma patients undergoing an autotransplant.
- HyperAcute GVHD: risk factors, outcomes, and clinical implications.
- Second autologous or allogeneic transplantation after the failure of first autoGraft in patients with multiple myeloma.
- Rituximab-induced Acute liver failure after an allogeneic transplantation for chronic myeloid leukemia.
- Nonmyeloablative stem cell transplantation for chronic myeloid Leukemia.
- Clinical efficacy of lorazepam in prophylaxis of anticipatory, Acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial.
- Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR.
- High-dose chemotherapy and autologous hematopoietic progenitor Cell transplantation for non-Hodgkin''s lymphoma in patients >65 years of age.
- A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem Cells in patients with non-Ho...
- Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous Leukemia in the imatinib era.
- Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem Cell transplantation.
- Vectors and target Cells for gene therapy of blood diseases.
- High incidence of vitamin D deficiency in patients undergoing allogeneic stem Cell transplantation.
- Impairment of filgrastim-induced stem Cell mobilization after prior lenalidomide in patients with multiple myeloma.
- Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.
- Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem Cell transplantation in patients with advanced lympho...
- Assessing the charges associated with hematopoietic stem Cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hema...
- Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem Cell transplantation for high-risk CD33 positive myeloid le...
- Hematopoietic progenitor cell collection in patients with chronic myelogenous Leukemia in complete cytogenetic remission after imatinib mesylate therapy.
- Poor hematopoietic stem Cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma.
- Treatment of FLT3-ITD-positive Acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
- Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk Acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity condi...
- Transfection of interleukin-12 cDNAs into tumor Cells induces cytotoxic immune responses against native tumor: implications for tumor vaccination.
- CR represents an early index of potential long survival in multiple Myeloma.
- Results of a retrospective single institution Analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell trans...
- Phase II trial of high-dose topotecan, melphalan and CY with autologous stem Cell support for multiple myeloma.
- Risk factors associated with late cytomegalovirus reactivation after allogeneic stem Cell transplantation for hematological malignancies.
- Autologous stem Cell transplantation is safe and feasible in elderly patients with multiple myeloma.
- Construction of a recombinant adeno-associated virus (rAAV) vector expressing murine interleukin-12 (IL-12).
- Strongyloidiasis after unrelated nonmyeloablative allogeneic stem Cell transplantation.
- Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for Acute lymphoblastic leukemia.
- Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type p53.
- A new syndrome of familial aplastic Anemia and chronic liver disease.
Schools
University of Karachi Dow Medical College
Wright State University Hospital
University Conn
NciNih
NIH
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Prostate Cancer Screening Exam (DRE)
- View All
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Antiphospholipid Syndrome (APS)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
National Institutes of Health Clinical Center -
Wright State University -
Dow Medical College
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1649364886 | |
| NPPES Provider LastName | QAZILBASH | |
| NPPES Provider FirstName | MUZAFFAR | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Pulmonary Disease | |
| Total Claim Count | 499.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 29.0 | |
| Percent Opioid Claims | 5.81 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1649364886 |
| Last Name Of The Provider | QAZILBASH |
| First Name Of The Provider | MUZAFFAR |
| View All |
Similar Doctors
|
Dr. Muffaddal S. Morkas, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anna Belcheva, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yvonne H. Sada, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patrick H. Archie, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John Thachil, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dejka M. Araujo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Donna M. Weber, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Joan M. Bull, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Naval G. Daver, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tariq Muzzafar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shi-Ming Tu, MD |
|
|
Dr. Stefan O. Ciurea, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marco G. De Lima, MD |
|
|
Dr. Syed W. Yusuf, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Werner A. Bleyer, MD
This Doctor is OpenDoctor Recommended.
|